Kinnevik invests USD 100m in Oviva, Europe's leading provider of AI-enabled chronic care
Kinnevik AB (publ) ("Kinnevik") today announced it has invested USD 100m in Oviva as part of a USD 220m Series D financing round. Oviva is a leading European provider of digital care for weight-related and chronic conditions. This investment reflects Kinnevik’s conviction in the company’s category leadership, ability to scale, and the long-term vision of its exceptional founders. With the investment, Oviva becomes one of Kinnevik’s largest companies, further supporting the portfolio’s growth, profitability and maturity profile.
For further information, visit www.kinnevik.com or contact:
Torun Litzén, Director Investor Relations Phone +46 (0)70 762 00 50 Email press@kinnevik.com
Email: press@kinnevik.com
Kinnevik is a leading growth investor on a mission to redefine industries and create remarkable growth companies. We are an active owner and operational partner, providing patient capital to challenger technology-enabled businesses in Europe and the US. Our passionate founders are building tomorrow’s leaders within healthcare, software and climate, making everyday life easier and better for people around the world. We invest at all stages of a company’s growth journey, always determined to create long-term value. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.